AKT1 and ovarian cancer: We and others have shown that highly selective small-molecule inhibitors of LPAAT-β can inhibit proliferation and suppress the activation of proteins in the phosphoinositide-3-kinase (PI3K)/AKT pathway, including AKT, mTOR, and S6K in human microvascular endothelial cells and ovarian cancer cell lines [14].